TLR2 agonist PAM3 similarly induced monocytes from Lupus patients to preferentially differentiate into M2-like macrophages, which represented a novel approach to the therapy of SLE (Horuluoglu et al., 2019). The gene discussed is TLR2; the disease is systemic lupus erythematosus.